NovoCure Ltd

038

Company Profile

  • Business description

    NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

  • Contact

    Grenville Street
    No. 4 The Forum, Second Floor
    St. HelierJE2 4UF
    JEY

    T: +44 1534756700

    E: [email protected]

    https://www.novocure.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2026

    Employees

    1,605

Stocks News & Analysis

stocks

SpaceX rally continues, expanding sky-high valuations

SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.
stocks

This US AI champion’s stock is too cheap to ignore

Even as competition looks likely to build, the company remains a leading wide-moat business securely at the center of the AI ecosystem.
stocks

Why SpaceX is coming to your Super Fund

Most Australians will end up owning SpaceX — whether they like it or not.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,047.3025.90-0.29%
CAC 408,445.7022.28-0.26%
DAX 4025,032.856.050.02%
Dow JONES (US)51,564.7072.150.14%
FTSE 10010,373.2726.43-0.25%
HKSE23,924.81387.35-1.59%
NASDAQ26,517.93496.281.91%
Nikkei 22571,250.06196.570.28%
NZX 50 Index13,495.63132.320.99%
S&P 5007,500.5880.481.08%
S&P/ASX 2008,828.7027.90-0.32%
SSE Composite Index4,090.4817.59-0.43%

Market Movers